Capsule Endoscopy Market Size
Capsule Endoscopy Market reached US$ 479.13 million in 2025 and is expected to reach US$ 883.50 million by 2033, growing with a CAGR of 8.7% during the forecast period 2026–2033.
Capsule endoscopy is a procedure in which a large vitamin pill and a small capsule are swallowed. A tiny wireless camera inside the capsule takes pictures as it travels through the small intestine. Images are transmitted to a recording device worn around the waist on a belt.
Capsule Endoscopy Market Scope
Metrics | Details |
| Market CAGR | 8.7% |
| Segments Covered | By Product, By Application, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For more details on this report Request for Sample
Capsule Endoscopy Market Dynamics
The factors influencing the global capsule endoscopy market are the increasing technological advancements in endoscopy procedures.
The increasing technological advancements in endoscopy procedures is expected to drive the global capsule endoscopy market in the forecast period
The fiberoptic endoscope (fiberscope) era has given way to the video scope and, more recently, the capsule endoscope. Video endoscopy will continue to be the most common type of endoscopy for the next 5-10 years, but diagnostic procedures such as colonoscopy are expected to be performed by capsule endoscopy. Because of its convenience and noninvasiveness, capsule endoscopy has revolutionized the management of small-bowel diseases. Capsule endoscopy is a standard procedure to diagnose obscure gastrointestinal bleeding, Crohn's disease, small-bowel tumours, and polyposis syndrome.
For instance, on November 15, 2021, PillCam Small Bowel 3 system for remote endoscopy procedures. The PillCam SB3 @HOME program combines Medtronic's PillCam technology with Amazon logistics, aiming to provide patients with timely and accurate results from the comfort of their own homes. PillCam SB3 @HOME is a telehealth option for direct visualization and monitoring of the small bowel, which can help detect lesions that are not detected by upper and lower endoscopy and may: indicate Crohn's disease, locate obscure bleeding, or identify sources of iron deficiency anemia (IDA).
Limitations associated with the use of capsule endoscopy is expected to hamper the market growth
While the capsule is the best way to see the inside of the small intestine, it has many inherent limitations and problems, and the most important is that it does not allow for therapy. Because of the capsule's rapid transit and blurry, unintelligible photographs, abnormalities in some areas of the intestine are missed. Retained stool or food debris can also blur the images. The primary risk of capsule endoscopy is device retention in the small bowel. The risk is very low, about one to two percent, in patients who have the test to evaluate for bleeding. The risk may rise to four to five percent in Crohn's disease patients. The majority of cases of capsule retention resolve spontaneously after a brief delay in the passage of the capsule, and the majority of patients have no symptoms at all. As a result, proper bowel preparation is essential prior to the capsule endoscopy. Reviewing tens of thousands of photographs takes a significant amount of time for the conscientious physician.
Capsule Endoscopy Market Segmentation Analysis
Based on product, the capsule endoscopes segment is expected to dominate the market
Capsule endoscopy involves using a swallowed video capsule to photograph the inside of the gastrointestinal tract. The main applications are examinations of the oesophagus, stomach, colon, and small and large intestines. Traditional endoscopes are inserted transorally or transanally, which can be uncomfortable for the patient, particularly because the small intestine can be difficult to reach during a traditional endoscopic examination. Many companies are manufacturing capsule endoscopes for the examination of different parts. The endoscope's design also increases the possibility of damage or lesions in the organs being examined. This digestible camera is the primary medical device used in a capsule endoscope procedure. A capsule endoscope is a small wireless device that can image the gastrointestinal tract. The receiver carried by the patient collects the data transmitted from the pill cam.
Capsule Endoscopy Market Geographical Analysis
North America region is expected to hold the largest market share in the global capsule endoscopy market
The growing preference for minimally invasive screening procedures and the adoption of technologically advanced products and systems. Furthermore, improved healthcare infrastructure and rising awareness about the early detection of diseases such as gastrointestinal disorders, Ambulatory surgery centers, and other chronic conditions are driving market growth in the region.
For instance, 75 million endoscopies are performed in the United States every year, with 51.5 million, or 68 percent, being gastrointestinal endoscopies. Furthermore, on November 15th, 2021, the US Food and Drug Administration (FDA) approved the PillCam Small Bowel 3 system for remote endoscopy procedures.
Capsule Endoscopy Market Key Players
The global capsule endoscopy market is highly competitive with FDA approvals, mergers, and product launches. Some of the key players are Given Imaging (Medtronic Plc), Olympus Corporation, IntroMedic, Co. Ltd., Chongqing Jinshan Science & Technology (Group) Co., Ltd., CapsoVision, RF System lab, Check-Cap, Advin Health Care.
Medtronic Plc
Overview: Medtronic plc is a medical device company. Medtronic's operational and executive headquarters are in Minneapolis, Minnesota, in the United States. The company was founded in 1949. The Company operates in four segments: Cardiac and Vascular Group, Restorative Therapies Group, Minimally Invasive Technologies Group, and Diabetes Group.
Product Portfolio: The PillCam capsule endoscopy platform produces clear images of the oesophagus, stomach, small bowel, and colon utilizing innovative visualization technology. This non-invasive platform enables doctors to detect GI abnormalities, track disease activity, and evaluate treatment efficacy.
Global Recent Developments
- February 2026: Olympus Corporation strengthened its U.S. presence by introducing next-generation capsule endoscopy systems for improved gastrointestinal visualization.
- January 2026: CapsoVision Inc. launched upgraded capsule platforms with panoramic imaging technology to improve small bowel diagnostics.
- December 2025: IntroMedic Co., Ltd. expanded distribution of its capsule endoscopy systems across North America, focusing on AI-based analysis tools.
- November 2025: CapsoVision Inc. submitted an FDA Breakthrough Device application for its CapsoCam UGI system aimed at early pancreatic cancer detection.
- September 2025: Medtronic plc upgraded its PillCam™ SB3 system with AI-powered image analysis and cloud-based reporting, improving diagnostic efficiency and reducing review time.
- August 2025: EU-backed ESOHISTO project launched to advance next-generation capsule endoscopy technology with improved imaging for clinical applications.
- January 2025: CapsoVision Inc. received FDA clearance for CapsoCam Plus® for pediatric use, expanding applications in minimally invasive GI diagnostics.
